New research gives hope to COVID-19 long haul carriers
Ohio News Time
Long-haul carriers often suffer from chronic and debilitating conditions for months or years after the initial COVID-19 infection. study found that the symptoms of long-distance transporters are exactly the same as those of a common illness called mast cell activation syndrome that can be treated with readily available drugs. Currently, there are several national clinical trials enrolling patients using mast cell drugs such as Montelukast and low-dose naltrexone available at ClinicalTrials.gov.